

Silicon Laboratories Inc.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

	Three Months Ended		Nine Months Ended	
	October 1, 2022	October 2, 2021	October 1, 2022	October 2, 2021
Revenues	\$269,817	\$ 184,831	\$766,781	\$ 512,180
Cost of revenues	104,232	75,322	281,521	214,619
Gross profit	165,585	109,509	485,260	297,561
Operating expenses:				
Research and development	84,624	72,656	245,677	201,503
Selling, general and administrative	50,738	46,128	144,398	131,535
Operating expenses	135,362	118,784	390,075	333,038
Operating income (loss)	30,223	(9,275)	95,185	(35,477)
Other income (expense):				
Interest income and other, net	4,672	1,476	9,616	3,100
Interest expense	(1,527)	(6,595)	(4,874)	(24,405)
Income (loss) from continuing operations before income taxes	33,368	(14,394)	99,927	(56,782)
Provision for income taxes	14,188	9,386	36,871	12,543
Equity-method earnings	1,819	4,040	2,985	5,938
Income (loss) from continuing operations	20,999	(19,740)	66,041	(63,387)
Income from discontinued operations, net of income taxes	--	2,106,796	--	2,183,884
Net income	\$ 20,999	\$2,087,056	\$ 66,041	\$2,120,497
Basic earnings (loss) per share:				
Continuing operations	\$ 0.62	\$ (0.45)	\$ 1.84	\$ (1.44)
Net income	\$ 0.62	\$ 48.11	\$ 1.84	\$ 48.08
Diluted earnings (loss) per share:				
Continuing operations	\$ 0.60	\$ (0.45)	\$ 1.79	\$ (1.44)
Net income	\$ 0.60	\$ 46.76	\$ 1.79	\$ 46.71
Weighted-average common shares outstanding:				
Basic	34,079	43,385	35,935	44,103
Diluted	34,779	44,634	36,968	45,394

Silicon Laboratories Inc.
Condensed Consolidated Balance Sheets
(In thousands, except per share data)
(Unaudited)

	October 1, 2022	January 1, 2022
Assets		
Current assets:		
Cash and cash equivalents	\$ 483,277	\$1,074,623
Short-term investments	893,131	964,582
Accounts receivable, net	76,672	98,313
Inventories	88,447	49,307
Prepaid expenses and other current assets	84,109	51,748
Total current assets	1,625,636	2,238,573
Property and equipment, net	151,610	146,516
Goodwill	376,389	376,389
Other intangible assets, net	91,650	118,978
Other assets, net	91,012	77,839
Total assets	\$2,336,297	\$2,958,295
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 81,676	\$ 47,327
Current portion of convertible debt, net	--	450,599
Deferred revenue and returns liability	11,705	13,849
Other current liabilities	112,320	157,052
Total current liabilities	205,701	668,827
Convertible debt, net	529,062	--
Other non-current liabilities	49,890	77,044
Total liabilities	784,653	745,871
Commitments and contingencies		
Stockholders' equity:		
Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued	--	--
Common stock – \$0.0001 par value; 250,000 shares authorized; 33,530 and 38,481 shares issued and outstanding at October 1, 2022 and January 1, 2022, respectively	3	4
Retained earnings	1,568,108	2,214,839
Accumulated other comprehensive loss	(16,467)	(2,419)
Total stockholders' equity	1,551,644	2,212,424
Total liabilities and stockholders' equity	\$2,336,297	\$2,958,295

Silicon Laboratories Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Nine Months Ended	
	October 1, 2022	October 2, 2021
Operating Activities		
Net income	\$ 66,041	\$2,120,497
Adjustments to reconcile net income to net cash provided by operating activities of continuing operations:		
Income from discontinued operations, net of income taxes	--	(2,183,884)
Depreciation of property and equipment	16,514	12,925
Amortization of other intangible assets	27,328	33,971
Amortization of debt discount and debt issuance costs	1,492	17,278
Loss on extinguishment of convertible debt	3	3,370
Stock-based compensation expense	43,213	36,916
Equity-method earnings	(2,985)	(5,938)
Deferred income taxes	(13,126)	(3,132)
Changes in operating assets and liabilities:		
Accounts receivable	21,641	22,573
Inventories	(39,100)	(11,320)
Prepaid expenses and other assets	(28,404)	33,536
Accounts payable	26,694	(4,522)
Other current liabilities and income taxes	17,962	(10,981)
Deferred revenue and returns liability	(2,144)	(1,657)
Other non-current liabilities	(7,713)	(11,388)
Net cash provided by operating activities of continuing operations	127,416	48,244
Investing Activities		
Purchases of marketable securities	(579,507)	(1,212,572)
Sales of marketable securities	42,952	194,492
Maturities of marketable securities	597,399	173,924
Purchases of property and equipment	(20,057)	(19,468)
Purchases of other assets	--	(578)
Net cash provided by (used in) investing activities of continuing operations	40,787	(864,202)
Financing Activities		
Payments on debt	(21)	(140,572)
Repurchases of common stock	(681,695)	(688,373)
Payment of taxes withheld for vested stock awards	(14,732)	(21,393)
Proceeds from the issuance of common stock	6,366	8,619
Net cash used in financing activities of continuing operations	(690,082)	(841,719)
Discontinued Operations		
Operating activities	(69,467)	69,685
Investing activities	--	2,747,684
Net cash provided by (used in) discontinued operations	(69,467)	2,817,369
Increase (decrease) in cash and cash equivalents	(591,346)	1,159,692
Cash and cash equivalents at beginning of period	1,074,623	202,720
Cash and cash equivalents at end of period	<u>\$ 483,277</u>	<u>\$1,362,412</u>

Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

<u>Non-GAAP Income Statement Items</u>	<u>Three Months Ended October 1, 2022</u>					
	<u>GAAP Measure</u>	<u>GAAP Percent of Revenue</u>	<u>Stock Compensation Expense</u>	<u>Intangible Asset Amortization</u>	<u>Non- GAAP Measure</u>	<u>Non-GAAP Percent of Revenue</u>
Revenues	\$269,817					
Gross profit	165,585	61.4%	\$288	\$ --	\$165,873	61.5%
Research and development	84,624	31.4%	8,788	7,305	68,531	25.4%
Selling, general and administrative	50,738	18.8%	6,874	829	43,035	15.9%
Operating expenses	135,362	50.2%	15,662	8,134	111,566	41.3%
Operating income	30,223	11.2%	15,950	8,134	54,307	20.1%

<u>Non-GAAP Earnings Per Share and Income Tax Rate</u>	<u>Three Months Ended October 1, 2022</u>							
	<u>GAAP Measure</u>	<u>GAAP Tax Percentage Rate</u>	<u>Stock Compensation Expense</u>	<u>Intangible Asset Amortization</u>	<u>Equity-Method Investment Adjustments</u>	<u>Income Tax Adjustments</u>	<u>Non- GAAP Measure</u>	<u>Non-GAAP Tax Percentage Rate</u>
Income before income taxes and equity-method earnings	\$35,187		\$15,950	\$8,134	\$(1,819)	\$ --	\$57,452	
Provision for income taxes	<u>14,188</u>	40.3%				1,052	<u>15,240</u>	26.5%
Net income	\$20,999						\$42,212	
Diluted shares outstanding	34,779						34,779	
Diluted earnings per share	\$ 0.60						\$ 1.21	

Unaudited Forward-Looking Statements Regarding Business Outlook**
(In millions, except per share data)

Business Outlook	Three Months Ending December 31, 2022		
	GAAP Measure	Non-GAAP Adjustments*	Non-GAAP Measure
Gross margin	60%	0%	60%
Operating expenses	\$132	\$(23)	\$109
Effective tax rate	35%	(10)%	25%
Diluted earnings per share - low	\$0.35	\$0.58	\$0.93
Diluted earnings per share - high	\$0.45	\$0.58	\$1.03

* Non-GAAP adjustments include the following estimates: stock compensation expense of \$16.9 million, intangible asset amortization of \$6.7 million and the associated tax impact from the aforementioned items.

** These financial schedules contain forward-looking statements based on Silicon Labs' current expectations. The words "believe," "estimate," "expect," "intend," "anticipate," "plan," "project," "will" and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally; risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of COVID-19 on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of anticipated share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. References in these financial schedules to Silicon Labs shall mean Silicon Laboratories Inc.